| Bristol-Myers Squibb27 programs in shared conditions | 20 · 10 with both in phase 3Carcinoma, Non-Small-Cell Lung, Cardiomyopathy, Hypertrophic, Colorectal Neoplasms +17 | xanomeline, trospium, trospium chloride +7 | - Jiangsu HengRui Medicine Co., Ltd.’s trastuzumab rezetecan vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Breast Neoplasms, NCT05814354)
- Jiangsu HengRui Medicine Co., Ltd.’s Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Pancreatic Neoplasms, NCT07238283)
- Jiangsu HengRui Medicine Co., Ltd.’s KRAS G12D Inhibitor HRS-4642 added to Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Pancreatic Neoplasms, NCT07296341)
- and 3 more
|
| Hoffmann-La Roche31 programs in shared conditions | 20 · 5 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Type 2 +17 | trontinemab, inavolisib, giredestrant +8 | - Jiangsu HengRui Medicine Co., Ltd.’s HRS-8080 vs pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06555068)
- Jiangsu HengRui Medicine Co., Ltd.’s trastuzumab rezetecan vs pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT07196774)
- Jiangsu HengRui Medicine Co., Ltd.’s trastuzumab rezetecan vs Ado-Trastuzumab Emtansine (US & EU rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06126640)
- and 3 more
|
| AstraZeneca69 programs in shared conditions | 36 · 20 with both in phase 3Asthma, Atherosclerosis, Biliary Tract Neoplasms +33 | benralizumab, tezepelumab, BFF MDI +7 | - Jiangsu HengRui Medicine Co., Ltd.’s Anti-CTLA-4 Monoclonal Antibody SHR-8068 in a combination vs durvalumab (US & EU rights: AstraZeneca) (Biliary Tract Neoplasms, NCT07229625)
- Jiangsu HengRui Medicine Co., Ltd.’s adebrelimab in a combination vs durvalumab (US & EU rights: AstraZeneca) (Biliary Tract Neoplasms, NCT07229625)
- AstraZeneca’s sonesitatug vedotin in a combination vs apatinib (most trials: Jiangsu HengRui Medicine Co., Ltd.) (Stomach Neoplasms, NCT06346392)
|
| Merck & Co., Inc31 programs in shared conditions | 25 · 10 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Hypercholesterolemia +22 | sacituzumab tirumotecan, patritumab deruxtecan, intismeran autogene +8 | - Jiangsu HengRui Medicine Co., Ltd.’s ruzaltatug rezetecan in a combination vs sacituzumab tirumotecan (most trials: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07895992)
- Jiangsu HengRui Medicine Co., Ltd.’s trastuzumab rezetecan in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Triple Negative Breast Neoplasms, NCT07679360)
- Jiangsu HengRui Medicine Co., Ltd.’s adebrelimab in a combination vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Triple Negative Breast Neoplasms, NCT07679360)
|
| Innovent Biologics, Inc.21 programs in shared conditions | 17 · 8 with both in phase 3Breast Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms +14 | Anti-HER2 Antibody-drug Conjugate IBI354, Anti-CTLA-4 Monoclonal Antibody IBI310, Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 +7 | - Jiangsu HengRui Medicine Co., Ltd.’s Anti-CTLA-4 Monoclonal Antibody SHR-8068 in a combination vs sintilimab (most trials: Innovent Biologics, Inc.) (Carcinoma, Hepatocellular, NCT06618664)
- Jiangsu HengRui Medicine Co., Ltd.’s HRS-7058 in a combination vs fulzerasib (most trials: Innovent Biologics, Inc.) (Carcinoma, Non-Small-Cell Lung, NCT07601048)
- Jiangsu HengRui Medicine Co., Ltd.’s HRS-4729 in a combination vs mazdutide (most trials: Innovent Biologics, Inc.) (Diabetes Mellitus, Type 2, NCT07843862)
|